Position in GNLX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$134,829
+$24,545 QoQ
Shares Held
44,794
-1.7% QoQ
Ownership
0.099%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#26
of 72 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Creative Planning holds $457,365,908 across 219 Biotechnology names. GNLX ranks #182 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
127,672 | $63,418,511 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
36,949 | $23,039,178 | |
| 3 | EXEL |
Exelixis, Inc.
|
270,292 | $14,706,586 | |
| 4 | INCY |
Incyte Corp
|
110,664 | $12,544,870 | |
| 5 | CYTK |
Cytokinetics Inc
|
141,939 | $12,091,783 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
64,120 | $12,008,393 | |
| 7 | ARGX |
Argenx SE
|
12,744 | $11,823,500 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
153,161 | $8,763,872 |
All Filings in GNLX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $134,829 | 44,794 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $110,284 | 45,572 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $191,002 | 43,808 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $193,653 | 46,108 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $126,348 | 44,024 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $113,888 | 42,181 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $101,539 | 43,025 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||